Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Oraxol in Solid Tumors
NCT03892018Phase 1Terminated
- Sponsor
- Athenex
- Start
- Aug 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paclitaxel + encequidar in solid tumor (2 arms), sponsored by Athenex. Primary endpoint: Concentration-time profile of Oral Paclitaxel in plasma at 168 hours. Started Aug 2019; status: terminated.
02
Drugs
paclitaxel + encequidar
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03892018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892018.